A detailed history of Oppenheimer Asset Management Inc. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 29,110 shares of ITCI stock, worth $2 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
29,110
Previous 34,798 16.35%
Holding current value
$2 Million
Previous $2.49 Million 19.18%
% of portfolio
0.03%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$64.37 - $75.65 $366,136 - $430,297
-5,688 Reduced 16.35%
29,110 $2.01 Million
Q4 2023

Feb 13, 2024

BUY
$46.37 - $73.65 $17,342 - $27,545
374 Added 1.09%
34,798 $2.49 Million
Q3 2023

Nov 07, 2023

BUY
$52.09 - $64.1 $154,655 - $190,312
2,969 Added 9.44%
34,424 $1.79 Million
Q2 2023

Aug 02, 2023

SELL
$54.67 - $66.44 $109,230 - $132,747
-1,998 Reduced 5.97%
31,455 $1.99 Million
Q1 2023

May 10, 2023

BUY
$43.8 - $56.99 $182,208 - $237,078
4,160 Added 14.2%
33,453 $1.81 Million
Q4 2022

Feb 06, 2023

SELL
$44.07 - $54.45 $51,694 - $63,869
-1,173 Reduced 3.85%
29,293 $1.55 Million
Q3 2022

Nov 14, 2022

BUY
$42.7 - $59.99 $507,147 - $712,501
11,877 Added 63.89%
30,466 $1.42 Million
Q2 2022

Aug 08, 2022

SELL
$43.0 - $65.64 $222,740 - $340,015
-5,180 Reduced 21.79%
18,589 $1.06 Million
Q1 2022

May 12, 2022

BUY
$38.74 - $62.09 $197,109 - $315,913
5,088 Added 27.24%
23,769 $1.46 Million
Q4 2021

Feb 02, 2022

BUY
$35.2 - $53.42 $93,315 - $141,616
2,651 Added 16.54%
18,681 $978,000
Q3 2021

Nov 12, 2021

BUY
$28.72 - $42.49 $460,381 - $681,114
16,030 New
16,030 $598,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $6.47B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Oppenheimer Asset Management Inc. Portfolio

Follow Oppenheimer Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.